Fisher & Paykel Healthcare (FRA:FPLB) ROCE %: 31.36% (As of Mar. 2026)


FRA:FPLB Fisher & Paykel Healthcare Corp Ltd FRA:FPLB
91 GF Score
Price €18.40
GF Value €21.23
! 3 Warning Signs
View Full Analysis

What is Fisher & Paykel Healthcare ROCE %?

Fisher & Paykel Healthcare FRA:FPLB -3.66% 91 ROCE % is 31.36% as of Mar. 2026. GuruFocus rates FRA:FPLB with a GF Score™ of 91/100 and a GF Value™ of €21.23. The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Fisher & Paykel Healthcare's annualized ROCE % for the quarter that ended in Mar. 2026 was 31.36%.

Fisher & Paykel Healthcare  (FRA:FPLB) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Fisher & Paykel Healthcare ROCE % Related Terms

Fisher & Paykel Healthcare ROCE % Historical Data

* Premium members only.

The historical data trend for Fisher & Paykel Healthcare's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fisher & Paykel Healthcare ROCE % Chart

Fisher & Paykel Healthcare Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 30.06 17.37 13.09 25.38 28.50

Fisher & Paykel Healthcare Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.50 21.37 28.64 26.74 31.36
FRA:FPLB
91GF Score
Fisher & Paykel Healthcare Corp Ltd FRA:FPLB
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fisher & Paykel Healthcare ROCE % Calculation

Fisher & Paykel Healthcare's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=324.653/( ( (1351.369 - 265.103) + (1443.488 - 251.811) )/ 2 )
=324.653/( (1086.266+1191.677)/ 2 )
=324.653/1138.9715
=28.50 %

Fisher & Paykel Healthcare's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Sep. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Sep. 2025 )(Q: Mar. 2026 )
=356.622/( ( (1318.746 - 236.204) + (1443.488 - 251.811) )/ 2 )
=356.622/( ( 1082.542 + 1191.677 )/ 2 )
=356.622/1137.1095
=31.36 %

(1) Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 31.36% mean?
Fisher & Paykel Healthcare (FRA:FPLB) has a ROCE % of 31.36% as of Mar. 2026.
Is Fisher & Paykel Healthcare's ROCE % too high?
Fisher & Paykel Healthcare's current ROCE % is 31.36%. The Medical Devices & Instruments industry median ROCE % is 2.23. Fisher & Paykel Healthcare's value of 31.36% is 1306.3% above this industry median. Overall, Fisher & Paykel Healthcare has a GF Score™ of 91/100, reflecting its overall financial health beyond just this single metric.
How does Fisher & Paykel Healthcare's ROCE % compare to ISRG and BDX?
Fisher & Paykel Healthcare's ROCE % of 31.36% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. Fisher & Paykel Healthcare's value of 31.36% is 1306.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fisher & Paykel Healthcare's current ROCE % of 31.36% is 1306.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fisher & Paykel Healthcare's current ROCE % is 31.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fisher & Paykel Healthcare stock overvalued right now?
Fisher & Paykel Healthcare (FRA:FPLB) has a current ROCE % of 31.36%. The stock's GF Value™ is €21.23, compared to a current price of €18.40 — trading 13.3% below its estimated fair value. The current ROCE % is 31.36% and 1306.3% above the Medical Devices & Instruments industry median of 2.23. Fisher & Paykel Healthcare's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Fisher & Paykel Healthcare (FRA:FPLB), the current ROCE % is 31.36% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fisher & Paykel Healthcare (FRA:FPLB) Overvalued in 2026?

Based on GuruFocus' analysis, Fisher & Paykel Healthcare stock appears to be undervalued. The current stock price of €18.40 is trading 13.3% below its estimated GF Value™ of €21.23.

Key valuation signals for FRA:FPLB:

  • ROCE %: 31.36%
  • GF Value™: €21.23 vs. price of €18.40 (13.3% below fair value)
  • GF Score™: 91/100 with 3 warning signs
  • Industry Position: 1306.3% above the Medical Devices & Instruments median

No single metric tells the full story. See the FRA:FPLB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fisher & Paykel Healthcare Business Description

Address 15 Maurice Paykel Place, East Tamaki, Auckland, NTL, NZL, 2013
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use of humidifiers, masks, and related consumables, and the number three player in the at-home treatment of sleep apnea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns roughly half of its revenue in North America, around a quarter in Europe, and approximately a fifth in Asia-Pacific. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand, Mexico, and China, and has a multichannel distribution model.
91GF Score

Get the complete analysis for FRA:FPLB

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€18.40
Price
€21.23
GF Value